Introduction Biologics are substantial in the treatment of different diseases; however, they can burden the healthcare systems due to their high cost. Biosimilars can help healthcare systems keep their financial sustainability and patients access to biological therapies. The research objective is to formulate a framework for integrating biosimilars in the private healthcare sector of the United Arab Emirates (UAE).
View Article and Find Full Text PDFBackground: In the evolving healthcare landscape of the United Arab Emirates (UAE), establishing cost-effectiveness thresholds (CETs) is pivotal to informing decision-makers about the value of health technologies.
Objective: This study aimed to establish CETs for the UAE that harmonise with international standards while reflecting the nation's unique healthcare needs and economic context.
Setting: United Arab Emirates.
Expert Rev Pharmacoecon Outcomes Res
October 2024
Background: Atopic dermatitis (AD) imposes a hidden burden through its negative effects on quality of life and productivity. We aim to estimate this hidden burden in adults and adolescents in Central and Eastern European (CEE) countries.
Methods: We created a burden of disease model to quantify AD's hidden burden.